<DOC>
	<DOCNO>NCT02978781</DOCNO>
	<brief_summary>This study two-part , multicenter , Phase 2a study evaluate efficacy , safety , tolerability , pharmacokinetics SAGE-217 60 adult subject essential tremor .</brief_summary>
	<brief_title>A Study Evaluate SAGE-217 Subjects With Essential Tremor</brief_title>
	<detailed_description>Part A study open-label design morning dose SAGE-217 7 day . Part B study double-blind , placebo-controlled , randomized withdrawal design morning dose 7 day .</detailed_description>
	<mesh_term>Tremor</mesh_term>
	<mesh_term>Essential Tremor</mesh_term>
	<criteria>Key Subject must diagnosis ET , define bilateral postural tremor kinetic tremor , involve hand forearm , visible persistent duration &gt; 5 year prior screen . Key Subject presence abnormal neurological sign tremor Froment 's sign . Subject presence know cause enhance physiological tremor . Subject concurrent recent exposure ( 14 day prior admission visit ) tremorogenic drug . Subject direct indirect trauma nervous system within 3 month onset tremor . Subject historical clinical evidence tremor psychogenic origin . Subject convince evidence sudden tremor onset evidence stepwise deterioration tremor .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Tremor</keyword>
</DOC>